Cart
sales@molnova.com
Canocapavir
CAS No. 2137847-19-7
Canocapavir( —— )
Catalog No. M35755 CAS No. 2137847-19-7
Canocapavir (ZM-H1505R) is a novel orally available HBV coat protein modulator with antiviral activity that induces conformational changes in the linker region of the HBV core protein, and can be used for the treatment of hepatitis B virus.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 454 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCanocapavir
-
NoteResearch use only, not for human use.
-
Brief DescriptionCanocapavir (ZM-H1505R) is a novel orally available HBV coat protein modulator with antiviral activity that induces conformational changes in the linker region of the HBV core protein, and can be used for the treatment of hepatitis B virus.
-
DescriptionCanocapavir (ZM-H1505R) has orally antiviral activity. Canocapavir is a HBV capsid inhibitor that can be used in the research of Chronic hepatitis B. .
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2137847-19-7
-
Formula Weight562.39
-
Molecular FormulaC27H21BrFN5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 300 mg/mL (533.44 mM; Ultrasonic (<60°C)
-
SMILESC(CC=1C=C2C(=CC1)NC(=O)N2)N3[C@@H](C=4C(=NN(C4)C5=CC=C(Br)C=C5)C6=CC=C(F)C=C6)OCC3=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf?sfvrsn=8544ca1e_3&download=true
molnova catalog
related products
-
HEC72702
HEC72702 is a novel potent, orally active inhibitor of HBV capsid assembly, inhibits HBV-DNA levels in HepG.2.2.15 cells with IC50 of 39 nM.
-
BCM-599
BCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo.
-
Bay 41-4109
A potent, non-nucleosidic inhibitor of HBV nucleocapsid maturation with IC50 of 0.05 uM.
